桑福德伯纳姆普雷比斯医学发现研究所的科学家们创造了一种药物，可以将干细胞引诱到受损组织并提高治疗效果 — 再生医学领域的科学首创和重大进步. 发现, 发表在《美国国家科学院院刊》上 (美国国家科学院院刊), could improve current stem cell therapies designed to treat such neurological disorders as spinal cord injury, 中风, amyotrophic lateral sclerosis?(如果) and other neurodegenerative disorders; and expand their use to new conditions, such as heart disease or arthritis.
Toxic cells (green) disappeared when mice with a neurodegenerative condition received both therapeutic stem cells (red) and the drug SDV1a-which corresponded with longer lives and delayed symptom onset. These results suggest that SDV1a can be used to improve the efficacy of stem cell treatments.
“The ability to instruct a stem cell where to go in the body or to a particular region of a given organ is the Holy Grail for regenerative medicine,” says Evan Y. Snyder, 医学博士. Ph.D., professor and director of the Center for Stem Cells & Regenerative Medicine at Sanford Burnham Prebys and senior author of the study. “现在, for the first time ever, we can direct a stem cell to a desired location and focus its therapeutic impact.”
